| Nuclear receptors and their selective pharmacologic modulators TP Burris, LA Solt, Y Wang, C Crumbley, S Banerjee, K Griffett, ... Pharmacological reviews 65 (2), 710-778, 2013 | 311 | 2013 |
| Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis CA Flaveny, K Griffett, BEDM El-Gendy, M Kazantzis, M Sengupta, ... Cancer cell 28 (1), 42-56, 2015 | 209 | 2015 |
| A liver-selective LXR inverse agonist that suppresses hepatic steatosis K Griffett, LA Solt, BEDM El-Gendy, TM Kamenecka, TP Burris ACS chemical biology 8 (3), 559-567, 2013 | 133 | 2013 |
| Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour S Banerjee, Y Wang, LA Solt, K Griffett, M Kazantzis, A Amador, ... Nature communications 5 (1), 5759, 2014 | 119 | 2014 |
| The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis K Griffett, RD Welch, CA Flaveny, GR Kolar, BA Neuschwander-Tetri, ... Molecular metabolism 4 (4), 353-357, 2015 | 95 | 2015 |
| The mammalian clock and chronopharmacology K Griffett, TP Burris Bioorganic & medicinal chemistry letters 23 (7), 1929-1934, 2013 | 57 | 2013 |
| Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease K Griffett, TP Burris Biochemical and Biophysical Research Communications 479 (3), 424-428, 2016 | 40 | 2016 |
| Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice WT Hodges, C Jarasvaraparn, D Ferguson, K Griffett, LE Gill, Y Chen, ... Journal of Biological Chemistry 298 (2), 2022 | 33 | 2022 |
| Fructose promotes cytoprotection in melanoma tumors and resistance to immunotherapy LM Kuehm, N Khojandi, A Piening, LE Klevorn, SC Geraud, ... Cancer immunology research 9 (2), 227-238, 2021 | 27 | 2021 |
| REV-ERB agonism improves liver pathology in a mouse model of NASH K Griffett, G Bedia-Diaz, B Elgendy, TP Burris PloS one 15 (10), e0236000, 2020 | 26 | 2020 |
| The orphan nuclear receptor TLX is a receptor for synthetic and natural retinoids K Griffett, G Bedia-Diaz, L Hegazy, IMS de Vera, US Wanninayake, ... Cell Chemical Biology 27 (10), 1272-1284. e4, 2020 | 25 | 2020 |
| Development of novel liver X receptor modulators based on a 1, 2, 4-triazole scaffold SS Goher, K Griffett, L Hegazy, M Elagawany, MMH Arief, A Avdagic, ... Bioorganic & medicinal chemistry letters 29 (3), 449-453, 2019 | 23 | 2019 |
| International union of basic and clinical pharmacology CXIII: Nuclear receptor superfamily—Update 2023 TP Burris, IMS de Vera, I Cote, CA Flaveny, US Wanninayake, ... Pharmacological reviews 75 (6), 1233-1318, 2023 | 22 | 2023 |
| Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases K Griffett, TP Burris Frontiers in medicine 10, 1102469, 2023 | 22 | 2023 |
| Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH RD Welch, C Billon, MK Losby, G Bedia-Diaz, Y Fang, A Avdagic, ... Metabolites 12 (3), 238, 2022 | 19 | 2022 |
| The role of REV-ERB in NASH K Griffett, ME Hayes, MP Boeckman, TP Burris Acta Pharmacologica Sinica 43 (5), 1133-1140, 2022 | 17 | 2022 |
| Inhibition of hepatotoxicity by a LXR inverse agonist in a model of alcoholic liver disease M Sengupta, K Griffett, CA Flaveny, TP Burris ACS pharmacology & translational science 1 (1), 50-60, 2018 | 17 | 2018 |
| A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis M Sengupta, S Abuirqeba, A Kameric, A Cecile-Valfort, A Chatterjee, ... PloS one 16 (3), e0249316, 2021 | 11 | 2021 |
| Antihyperlipidemic activity of gut-restricted LXR inverse agonists K Griffett, M Hayes, G Bedia-Diaz, K Appourchaux, R Sanders, ... ACS Chemical Biology 17 (5), 1143-1154, 2022 | 9 | 2022 |
| REV-ERB activation as a novel pharmacological approach for treating inflammatory pain S Makhija, JD Griffett, GB Veerakanellore, TP Burris, B Elgendy, K Griffett Frontiers in pharmacology 14, 1171931, 2023 | 7 | 2023 |
Subhashis BanerjeeThe University of VirginiaVerificeret mail på virginia.edu